Trade alert: BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) director Vincent Milano just spent US $ 91,000 to buy 75% more shares


While it might not be huge, we thought it was good to see that the BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) Director Vincent Milano recently bought US $ 91,000 worth of shares, for US $ 12.19 per share. While not a massive buy, it increased their stake by 75%, which is probably a good sign.

See our latest review for BioCryst Pharmaceuticals

The Last 12 Months of Insider Trading at BioCryst Pharmaceuticals

In fact, the recent purchase by Vincent Milano was the largest purchase of BioCryst Pharmaceuticals shares by an insider in the past twelve months, according to our records. This implies that an insider found the current price of US $ 12.50 per share attractive. This means that they have been optimistic about the company in the past, even though they may have changed their minds. While we still love to see insider buys, it makes less sense if the buys were made at much lower prices, as the opportunity they saw may have passed. Fortunately, the BioCryst Pharmaceuticals insider decided to buy shares at prices close to current prices. Vincent Milano has been the only individual insider to buy in the past year.

George Abercrombie abandoned 10,000 shares during the year. The average price per share was US $ 13.42. The chart below shows insider trading (by businesses and individuals) over the past year. If you want to know exactly who sold, for how much and when, just click on the graph below!

NasdaqGS: BCRX Insider Trading Volume November 25, 2021

I’d like BioCryst Pharmaceuticals better if I see big insider buys. In the meantime, watch this free list of growing companies with significant and recent insider buying.

Does BioCryst Pharmaceuticals have strong insider ownership?

For an ordinary shareholder, it is worth checking out how many shares are owned by company insiders. Strong insider ownership often makes company management more concerned with the interests of shareholders. It appears that BioCryst Pharmaceuticals insiders own 0.8% of the company, worth around $ 19 million. We’ve certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest an alignment between insiders and other shareholders.

So what does this data suggest about BioCryst Pharmaceuticals insiders?

Our data shows a small insider buy, but no sells, in the past three months. Net investment is not enough to encourage us much. We’re a little cautious about insider sales at BioCryst Pharmaceuticals. But we love that the insiders own a good chunk of the business. While we love to know what’s going on with insider ownership and trading, we also make sure to consider the risks a stock faces before making any investment decisions. For example, BioCryst Pharmaceuticals has 2 warning signs (and 1 which is potentially serious) we think you should be aware of.

But beware : BioCryst Pharmaceuticals May Not Be The Best Stock To Buy. So take a look at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are the persons who report their transactions to the relevant regulatory body. We currently account for open market transactions and private assignments, but not derivative transactions.

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents. Simply Wall St has no position in any of the stocks mentioned.

Do you have any feedback on this item? Are you worried about the content? Get in touch with us directly. You can also send an email to the editorial team (at)


Comments are closed.